Cargando…

Metabolomics Analysis Reveals Altered Metabolic Pathways and Response to Doxorubicin in Drug-Resistant Triple-Negative Breast Cancer Cells

This study aimed to investigate metabolic changes following the acquisition of resistance to doxorubicin in the triple-negative breast cancer (TNBC) cell line MDA-MB-231. Two drug-resistant cell lines, DOX-RES-50 and DOX-RES-100, were generated by treating MDA-MB-231 cells with doxorubicin for 24 h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rushing, Blake R., Molina, Sabrina, Sumner, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10383792/ https://www.ncbi.nlm.nih.gov/pubmed/37512572 http://dx.doi.org/10.3390/metabo13070865

Ejemplares similares

Metabolomics Analysis Reveals Novel Targets of Chemosensitizing Polyphenols and Omega-3 Polyunsaturated Fatty Acids in Triple Negative Breast Cancer Cells
por: Rushing, Blake R., et al.
Publicado: (2023)

A Review of Metabolic Targets of Anticancer Nutrients and Nutraceuticals in Pre-Clinical Models of Triple-Negative Breast Cancer
por: Wiggs, Alleigh, et al.
Publicado: (2022)

Comparison of Lysis and Detachment Sample Preparation Methods for Cultured Triple-Negative Breast Cancer Cells Using UHPLC–HRMS-Based Metabolomics
por: Rushing, Blake R., et al.
Publicado: (2022)

Commonalities in Metabolic Reprogramming between Tobacco Use and Oral Cancer
por: Rushing, Blake R., et al.
Publicado: (2022)

Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer
por: Fennell, Emily M. J., et al.
Publicado: (2023)

New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells
por: Ciocan-Cartita, Cristina Alexandra, et al.
Publicado: (2020)

Correction to: New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells
por: Ciocan-Cartita, Cristina Alexandra, et al.
Publicado: (2020)

Exploring the Contribution of (Poly)phenols to the Dietary Exposome Using High Resolution Mass Spectrometry Untargeted Metabolomics
por: Li, Yuan‐Yuan, et al.
Publicado: (2022)

Stable Isotope-Resolved Metabolomic Differences between Hormone-Responsive and Triple-Negative Breast Cancer Cell Lines
por: Winnike, Jason H., et al.
Publicado: (2018)

Exploratory Metabolomics Underscores the Folate Enzyme ALDH1L1 as a Regulator of Glycine and Methylation Reactions
por: Rushing, Blake R., et al.
Publicado: (2022)

Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer
por: Zeng, Weiwei, et al.
Publicado: (2023)

Metabolic Response of Triple-Negative Breast Cancer to Folate Restriction
por: Coleman, Michael F., et al.
Publicado: (2021)

Pharmacometabolomics reveals urinary diacetylspermine as a biomarker of doxorubicin effectiveness in triple negative breast cancer
por: Velenosi, Thomas J., et al.
Publicado: (2022)

The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells
por: Mentoor, Ilze, et al.
Publicado: (2021)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Mesenchymal Stem Cell-Induced Doxorubicin Resistance in Triple Negative Breast Cancer
por: Chen, Dar-Ren, et al.
Publicado: (2014)

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer
por: Berry, Jameson T.L., et al.
Publicado: (2020)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model
por: González-Ortiz, Alina, et al.
Publicado: (2022)

Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities
por: Lanning, Nathan J., et al.
Publicado: (2017)

Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer
por: Chen, Di, et al.
Publicado: (2019)

Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
por: Inao, Touko, et al.
Publicado: (2018)

Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo
por: Lothstein, Leonard, et al.
Publicado: (2020)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

Folate-Functionalized DNA Origami for Targeted Delivery of Doxorubicin to Triple-Negative Breast Cancer
por: Pal, Suchetan, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

ROS-responsive Galactosylated-nanoparticles with Doxorubicin Entrapment for Triple Negative Breast Cancer Therapy
por: Zhou, Jingyi, et al.
Publicado: (2023)

Metabolomic analysis reveals altered metabolic pathways in a rat model of gastric carcinogenesis
por: Gu, Jinping, et al.
Publicado: (2016)

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin
por: Krausz, Aimee E., et al.
Publicado: (2018)

Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway
por: Wu, Liqiong, et al.
Publicado: (2023)

Multi-Omics Analysis of NCI-60 Cell Line Data Reveals Novel Metabolic Processes Linked with Resistance to Alkylating Anti-Cancer Agents
por: Rushing, Blake R.
Publicado: (2023)

MUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
por: Goode, Gennifer, et al.
Publicado: (2017)

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
por: Xiao, Yi, et al.
Publicado: (2022)

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer
por: McKenna, Matthew T., et al.
Publicado: (2017)

Growth Inhibition of Triple-Negative Breast Cancer: The Role of Spatiotemporal Delivery of Neoadjuvant Doxorubicin and Cisplatin
por: Salerno, Dominick, et al.
Publicado: (2021)

Cytoprotective Effect of Vitamin D on Doxorubicin-Induced Cardiac Toxicity in Triple Negative Breast Cancer
por: Lee, Kevin J, et al.
Publicado: (2021)

Physiological, metabolomic, and transcriptomic reveal metabolic pathway alterations in Gymnocypris przewalskii due to cold exposure
por: Liu, Sijia, et al.
Publicado: (2023)

Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
por: Egelston, Colt A., et al.
Publicado: (2023)

Metabolic Alterations in Preneoplastic Development Revealed by Untargeted Metabolomic Analysis
por: Myllymäki, Henna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tc5vpt26640tk5a44q0a7ojfou